GLP-1 and Muscle Protein Synthesis for Improved Calorie Balance
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the management of obesity, inducing significant weight loss and improving metabolic parameters. However, emerging evidence suggests that these agents may contribute to unintended reductions in skeletal muscle mass, potentially exacerbating or precipitating various health complications.
Understanding Muscle Protein Synthesis and GLP-1
Muscle protein synthesis (MPS) is the process of building new muscle proteins, essential for maintaining lean mass. A key regulator of MPS is the molecular switch, mechanistic target of rapamycin (mTOR), which is activated during resistance training and abolished during periods of fasting or caloric restriction.
GLP-1RAs, such as semaglutide and tirzepatide, work by mimicking the GLP-1 hormone, increasing insulin secretion, slowing gastric emptying, and reducing appetite. While this creates a powerful caloric deficit, the body doesn't selectively burn fat; instead, it catabolizes all available tissues for fuel, including skeletal muscle.
The Risk of Muscle Loss on GLP-1 Medications
Research suggests that 25-39% of weight lost on GLP-1 medications like Ozempic may come from lean muscle mass. Adequate protein intake of 1.2-1.6g per kg body weight is crucial for muscle preservation during Ozempic treatment. Resistance training 2-3 times per week can also help mitigate muscle loss.
